3B3-PE38 targets and systemically depletes vRNA⁺ cells <i>in vivo</i>.

<p>Beginning on Day 28 after ART initiation 3B3-PE38 was added to the treatment regimen every other day (7 total doses: 4 at 1 µg/25 g followed by 3 at 5 µg/25 g). The ART only control includes mice treated for 28–64 days. (<b>A</b>) Reductions in cell-associated vRNA levels are presented as log10 differences in medians. Mann-Whitney tests were used to generate p values. (<b>B</b>) Reductions in cell-associated vRNA levels for all tissues in (A) are graphed alongside data from untreated mice (Wilcoxon rank-sum statistics with repeated measures corrections). (<b>C</b>) Quantitative ISH for No ART mice (<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003872#ppat-1003872-g002" target="_blank">Fig. 2</a>), ART only mice (<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003872#ppat-1003872-g002" target="_blank">Fig. 2</a>) and the ART+3B3-PE38 group revealed reductions in the total number of HIV RNA producing cells per gram. When no RNA⁺ cells were detected, then the number of RNA producing cells per gram tissue was set to 200 in the graph (Exact log rank tests with repeated measures corrections).